Proactive Investors - Run By Investors For Investors

Antibe Therapeutic's Phase 2B trial safety results for pain drug ATB-346 published in British Journal of Pharmacology

A new research article in the British Journal of Pharmacology highlights the success of Antibe's 2B GI safety trial for its lead pain treatment ATB-346
Toronto-based Antibe develops safer, non-addictive medicines for pain and inflammation

Antibe Therapeutics Inc (CVE:ATE), a commercial-stage healthcare company, alerted investors Tuesday about a new research article in the British Journal of Pharmacology regarding the successful 2B GI safety trial for its lead drug ATB-346.

ATB-346 is a hydrogen sulfide-releasing derivative of naproxen, a non-steroid anti-inflammatory drug that is used to relieve pain from various conditions.

READ: British Journal of Pharmacology research article

Non-steroidal anti-inflammatory drugs such as naproxen are common pain therapies for osteoarthritis and gout, but their use is associated with a high incidence of gastrointestinal ulceration and bleeding.

The results of the safety study published in the British Journal of Pharmacology provide evidence that ATB-346 is less toxic, but as effective as naproxen in alleviating pain, according to John Wallace, Antibe’s chief scientific officer.

“We are pleased that the results of our Phase 2B GI safety study for ATB-346 have been published in BJP,” Wallace said in a statement. “The results provide unequivocal evidence for a dramatic reduction of GI toxicity of ATB‐346 as compared to naproxen, with equivalent suppression of the enzyme (cyclooxygenase; COX) that produces substances that cause pain.”

Headquartered in Toronto, Antibe develops non-addictive medicines for pain and inflammation.

Contact Ellen Kelleher at [email protected]

View full ATE profile View Profile

Antibe Therapeutics Timeline

Related Articles

A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use